書誌事項
- タイトル別名
-
- Effect of Probucol Treatment on Blood Lipid Markers(Especially Malondialdehyde-modified Low-density Lipoproteins) in Type 2 Diabetic Patients with Hypercholesterolemia.
- プロブコール トウヨ ガ コウシケツショウ オ ガッペイ シタ 2ガタ トウニョウビョウ カンジャ ノ シシツ タイシャ ニ オヨボス コウカ : トクニ MDA-LDL ノ ケントウ オ チュウシン ト シテ
- 特にMDA-LDLの検討を中心として
この論文をさがす
抄録
Probucol is known to have an antioxidant effect, but its effect on serum malondialdehyde-modified LDL (MDA-LDL) is unknown. We studied the effect of 3-month probucol treatment on MDA-LDL and other lipids markers [total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), lipid peroxidation (LPO), lipoprotein a (Lp (a)), and remnant-like particle cholesterol (RLP-C)] in type 2 diabetic patients with hypercholesterolemia.<BR>At the start of treatment, MDA-LDL correlated positively with LPO, TC, LDL-C, and HbA1c (p<0.05). Probucol treatment significantly reduced MDA-LDL, LPO, TC, HDL-C, and LDL-C (p<0.05), although other markers were not changed. Furthermore, % change in MDA-LDL by probucol treatment also correlated positively with % changes in both LPO and HbAic.<BR>This data suggests that probucol reduced MDA-LDL in type 2 diabetic patients. Probucol is thus useful in improving dyslipidemia quantitatively and qualitatively in type 2 diabetic patients.
収録刊行物
-
- 糖尿病
-
糖尿病 45 (3), 199-204, 2002
一般社団法人 日本糖尿病学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390001204904756736
-
- NII論文ID
- 10008362743
- 130004338834
-
- NII書誌ID
- AN00166576
-
- ISSN
- 1881588X
- 0021437X
-
- NDL書誌ID
- 025094862
-
- 本文言語コード
- ja
-
- データソース種別
-
- JaLC
- NDL
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可
